Food and Staples Retailing Drug Retail


  • Pressure Grows to Create Drugs for ‘Superbugs’ Monday, 3 Jun 2013 | 1:45 AM ET
    A hospital epidemiologist and a geneticist at the National Institutes of Health Clinical Center in Bethesda, Md.

    Government officials, drug companies and medical experts, faced with outbreaks of antibiotic-resistant "superbugs", are pushing to speed up the approval of new antibiotics, the NYT reports.

  • Stocks to Shrug Off Blood-Pressure Drug Dispute Friday, 31 May 2013 | 4:29 PM ET

    A dispute within the FDA on whether to put new lung-cancer warnings on ARBs taken by millions of people is unlikely to have any significant effect on the manufacturers stocks.

  • Faber Report: Royalty Pharma to Raise Elan Bid Monday, 20 May 2013 | 10:32 AM ET
    Faber Report: Royalty Pharma to Raise Elan Bid

    A break down on the latest activity in mergers and acquisitions, with CNBC's David Faber.

  • What's Working in Pharma Monday, 13 May 2013 | 6:15 PM ET
    What's Working in Pharma

    Of the new drugs approved from 2004 through 2011, Quintiles was involved with 85 percent of the central nervous system drugs, 76 percent of oncology drugs and 72 percent of cardiovascular drugs. Mad Money host Jim Cramer explains why the stock is a buy.

  • Talking Numbers: Pfizer Flops Earnings Tuesday, 30 Apr 2013 | 3:15 PM ET
    Talking Numbers: Pfizer Flops Earnings

    Technical analyst Jeff Tomasulo is bearish on Pfizer after its big drop today. Fundamental analyst Pat Dorsey also isn't a buyer. (2:25)

  • Novartis Disputes Allegations Monday, 29 Apr 2013 | 1:11 PM ET
    Novartis Disputes Allegations

    CNBC's Andrea Day reports Swiss drug maker Novartis is disputing allegations in 2 U.S. federal lawsuits. The company is accused of wining and dining doctors.

  • Isis Takes on Huntington's Disease Wednesday, 24 Apr 2013 | 5:40 PM ET
    Isis Takes on Huntington's Disease

    Isis Pharmaceuticals CEO Stanley Crooke discusses his new technology Antisense and its role in helping huntington's disease.

  • J&J Tops Estimates on Newer Medicine Growth Tuesday, 16 Apr 2013 | 8:16 AM ET
    Johnson & Johnson products

    The pharmaceutical and medical devices company reported quarterly earnings and revenue Tuesday that exceeded Wall Street's expectations as growth of newer medicines for cancer, hepatitis C and blood clots offset declining sales of its treatments for heartburn and attention deficit disorder.

  • Global Growth Creates US Jobs: General Mills CEO Thursday, 11 Apr 2013 | 3:54 PM ET

    The "astonishing" growth of the middle class in emerging markets is benefiting General Mills and creating jobs in the U.S., CEO Ken Powell told CNBC's "Street Signs" on Thursday.

  • Red Hot Big Pharma Worth Owning Tuesday, 9 Apr 2013 | 6:25 PM ET
    Red Hot Big Pharma Worth Owning

    Not every stock needs to have a "turbo-charged" growth angle to it. Mad Money host Jim Cramer says big pharma stocks have been red hot, and discusses which ones are worth owning.

  • Johnson & Johnson, a Break-Up Play? Monday, 8 Apr 2013 | 6:25 PM ET
    Johnson & Johnson, a Break-Up Play?

    Investors should always have a high yielding stock in their portfolio. Big pharma stocks tend to do better when the economy isn't doing so well, explains Mad Money host Jim Cramer. A preview of Johnson & Johnson ahead of earnings.

  • Johnson & Johnson Hits All-Time High Monday, 1 Apr 2013 | 2:38 PM ET
    Johnson & Johnson Hits All-Time High

    Johnson & Johnson just won approval for a new diabetes drug, and the stock is at an all-time high today. Anthony Butler, Barclays, offers insight.

  • Biogen IDEC CEO on Multiple Sclerosis Pill Thursday, 28 Mar 2013 | 4:35 PM ET
    Biogen IDEC CEO on Multiple Sclerosis Pill

    Biotech has returned 20 percent for investors this year. Biogen IDEC CEO George Scangos, discusses the recent FDA approval of his company's drug, which is its first pill for multiple sclerosis.

  • Pay For Generic Drug Delay Monday, 25 Mar 2013 | 4:52 PM ET
    Pay For Generic Drug Delay

    The government says big pharma should not be allowed to pay generic drug makers to let them keep their costly branded drugs on the market longer, reports CNBC's Bertha Coombs.

  • Mixed Session For Generic Drugmakers Monday, 25 Mar 2013 | 1:38 PM ET
    Mixed Session For Generic Drugmakers

    CNBC's Seema Mody reports the latest from the Nasdaq: Drug makers Actavis and AstraZeneca reach an agreement to launch a Crestor generic in 2016.

  • AstraZeneca Settles Patent Dispute Monday, 25 Mar 2013 | 1:37 PM ET
    AstraZeneca Settles Patent Dispute

    AstraZeneca settled a patent dispute with generic drug maker Watson Laboratories over its cholesterol drug Crestor, reports CNBC's Bertha Coombs.

  • Beer and Africa: A Recipe for Profit? Monday, 25 Mar 2013 | 9:56 AM ET

    One sector that is yet to be truly tapped in Africa is the brewing industry, according to research firm Bernstein Research, which believes it is probably the most attractive region for long-term profit growth for global brewers.

  • One Options Trader Bets Walgreen Will See Red Thursday, 14 Mar 2013 | 3:16 PM ET

    Sometimes, when a stock surges on an analyst upgrade, it's high time to make a bearish bet. That's exactly what one big options trader did on Walgreen.

  • Confidence Back? Several Retailers Top Sales Forecasts Thursday, 7 Mar 2013 | 8:39 AM ET

    After a difficult January, when shoppers first felt the effect of a payroll tax hike that lowered take-home pay by 2 percent, some retailers got a little relief in February from growing employment and a rising stock market.

  • Alex Gorsky

    Containing health care costs, promoting innovation and the treatment of deadly diseases are among the biggest challenges the U.S. faces, Johnson and Johnson CEO Alex Gorsky said on Thursday.